GRACEcast Radiation Oncology Audio

By cancerGRACE - H. Jack West, MDMedicine Education

GRACEcast Radiation Oncology Audio episodes

June 19, 2013 Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
6 min
June 19, 2013 Can we improve on XALKORI? New agents for patients with an ALK-1 rearrangement
Dr. Mary Pinder reviews promising studies from ASCO 2013 on second gen. ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.
7 min
June 19, 2013 Can we harness our immune system to fight NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.
9 min
June 19, 2013 Can addition of a "heat shock protein inhibitor" to standard chemo improve outcomes in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.
7 min
June 15, 2013 Dr. Larry Einhorn: What is Your Opinion of Patients and Caregivers Searching the Internet for Information?
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
2 min
June 15, 2013 Dr. Karen Kelly: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.
2 min
June 15, 2013 Is there a best Avastin-containing regimen for first line and maintenance therapy in advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PARAMOUNT trial of maintenance therapy with the ECOG 4599 regimen vs. carboplatin/Alimta (pemetrexed)/Avastin (bevacizumab) followed by Alimta/Avastin maint.
13 min
June 13, 2013 Do you need Avastin in first line and maintenance therapy in advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
7 min
June 12, 2013 Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
2 min
June 12, 2013 Can we predict which patients will benefit from Tarceva based on a blood test?
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
8 min

About GRACEcast Radiation Oncology Audio

From the publisher's feed

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to…